Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 1999

View Archived Issues

Paracure gets notice of allowance for patent covering modified arglabin compounds

Dual-function anti-HIV microbicides/spermicidal agents still a focus at Hughes Institute

Fournier selects 15-deoxyspergualin derivative for clinical evaluation

Knoll/BASF Pharma pipeline update

DiagnoCure reaches agreement with DAKO for bladder cancer diagnostic

Yale and Alexion report preclinical data on xenotransplantation for spinal cord repair

Clinical data presented for Avax's autologous cancer vaccines

Allelix reports recent events related to compounds in development

Positive phase Ib results reported for Cerus's red blood cell pathogen inactivation system

Nortran's intractable cough treatment completes safety trial

Dura begins clinical program on Budesonide Spiros

Anticoagulants remain focus of research at Warner-Lambert

New Janssen compounds effective against HIV-1

RWJ-56110: design, synthesis and characterization of new peptidomimetic PAR-1 antagonist

Advances in pain program announced by Cambridge NeuroScience

Hydroxyurea tested as an alternative to PI in combination regimens in antiretroviral-naive subjects

Levonorgestrel-releasing IUD for treatment of dysmenorrhea secondary to endometriosis

Development of antisense-containing regimen for malignant melanoma to be fast-tracked

Zyprexa now heading for final approval for new indication

Thiadiazole proton pump inhibitors designed at Apotex

Wide series of HIV reverse transcriptase inhibitors in early development at DuPont

Inhibitors of matrix metalloproteinase enzymes disclosed by HMR

Two compounds resulting from Ligand-Glaxo Wellcome collaboration advance through the pipeline

ETA/ETB antagonist tezosentan is a promising parenteral treatment for acute conditions

AGI-1067 and related AtheroGenics compounds licensed to Schering-Plough

Abbott's ETA antagonist may also be indicated for diabetic nephropathy

Abbott licenses development, marketing rights to Theragyn from Antisoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...